Policy, Guidance and Material Reviews
The PhUSE Data Transparency Working Group, as an active player in the field, reviews on regular basis a number of deliverables produced by other key stakeholders in the form of guidances, policies or articles. In particular, the PhUSE Data Transparency Working Group was invited to the EMA Policy 0070 Stakeholders meetings to comment on earlier version of the External Guidance.
In addition, the Working Group has had a collaboration with TransCelerate on the topic and the 2 organisations provided each other comments on respective deliverables.
The Working Group also provided comments to Health Canada on their respective policy and guidance that were available for public review. The Working Group had an opportunity to provide feedback to the Cochrane organisation on their paper 'Interim guidance on how to decide whether to include clinical study reports and other regulatory documents into Cochrane reviews'.
Project Leads & Members
|Jean-Marc Ferran||Project Lead||PhUSEemail@example.com|
The PhUSE Data Transparency Working Group is always interested to review other organisations' deliverables. Please get in touch with Project Lead if you would like us to review or give input to your work.
There are no current reviews taking place at the moment.
- PhUSE Comments to EMA 'Publication and access to clinical-trial data', 2013 - Stakeholder 107, pages 87-92
- PhUSE Data Transparency Working Group’s Comments on Canada’s Gazette, Part 1 of 9. December 2017
- PhUSE Data Transparency Working Group’s Comments on Health Canada’s DraftGuidance for the Implementation of the Public Release of Clinical Information of 10 April 2018.